No Data
No Data
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment
Express News | Repare Therapeutics Inc - Cost and Headcount Reductions to Extend Cash Runway to Mid-2027
Express News | Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Cuts Target Price to $6